Camille Bedrosian compensation by year
Ultragenyx Pharmaceutical Summary Compensation Table · all 5 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Salary | $442,308 | $511,186 | $546,686 | $567,123 | $596,000 |
| Bonus | $210,000 | $0 | $0 | $0 | $0 |
| Stock awards | $990,000 | $878,150 | $695,392 | $1,653,212 | $2,007,768 |
| Option awards | $2,906,983 | $863,513 | $674,871 | $866,427 | $892,550 |
| Non-equity incentive | $189,274 | $230,076 | $297,731 | $249,260 | $246,750 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $107,727 | $13,891 | $0 | $8,700 | $12,200 |
| Total | $4,846,292 | $2,496,816 | $2,214,680 | $3,344,722 | $3,755,268 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed April 24, 2023, accession 0001308179-23-000757, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Ultragenyx Pharmaceutical Inc. filed document, accession 0001308179-23-000757. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 14,000 | $648,620 | — |
| PSU | 14,000 | $648,620 | — |
| RSU | 6,788 | $314,488 | — |
| RSU | 3,650 | $169,105 | — |
| RSU | 1,750 | $81,078 | — |
| PSU | 1,100 | $50,963 | — |
| Option | 1,344 | — | $67.55 |
| Option | 6,562 | — | $56.08 |
| Option | 24,900 | — | $67.37 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Ultragenyx Pharmaceutical’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Emil Kakkis | President and Chief Executive Officer | $12,140,330 |
| Mardi Dier | Former Chief Financial Officer and Executive Vice President | $4,436,756 |
| Camille Bedrosian · this page | Chief Medical Officer | $3,755,268 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $3,748,555 |
| John Pinion | Chief Quality Officer and Executive Vice President, Translational Sciences | $3,706,511 |
The full Ultragenyx Pharmaceutical compensation record
free company briefThis page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Ultragenyx Pharmaceutical proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.